Targeted immunotherapy for colorectal cancer: monoclonal antibodies and immunotoxins

Area of Science:

• Oncology
• Immunology
• Pharmacology

Background:

• Colorectal cancer (CRC) is a significant global health issue, ranking as the third most diagnosed cancer and second leading cause of cancer-related mortality.
• Current CRC treatments often lack sufficient therapeutic efficacy, necessitating the development of novel and more effective therapies.
• Immunotherapy has emerged as a promising treatment modality across various cancers, with several agents approved and undergoing clinical trials.

Purpose of the Study:

• To provide an overview of current agents used in targeted immunotherapy for colorectal cancer.
• To highlight the role of antibodies in cancer therapy, particularly in recognizing tumor-associated antigens.
• To discuss the strategy of arming antibodies with cytotoxic agents to improve anti-tumor efficacy.

Main Methods:

• Review of current literature on targeted immunotherapy for colorectal cancer.
• Analysis of the mechanisms of action for antibody-based therapies.
• Examination of strategies to enhance antibody efficacy, including combination therapies and antibody-drug conjugates.

Main Results:

• Antibodies are effective in targeting tumor-associated antigens on malignant cells.
• Monoclonal antibodies can be used alone or in combination therapies.
• Arming antibodies with cytotoxic agents enhances their ability to eliminate cancer cells and induce tumor regression.

Conclusions:

• Targeted immunotherapy, particularly using armed antibodies, represents a promising approach for improving colorectal cancer treatment outcomes.
• Further research and development of these agents are crucial for enhancing anti-tumor activity and patient survival.
• The review underscores the potential of antibody-based therapies in the evolving landscape of colorectal cancer treatment.